Trial · NCT03677154
Registered outcomes36
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 36
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants with Adverse Events | Baseline through approximately 90 days after last study treatment | |
| Primary | Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria (Cohort A) | 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days) | |
| Primary | PET-CT Objective Response Rate (ORR) at PRA According to Lugano 2014 Response Criteria as Determined by the Investigator (Cohort B) | 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days) | |
| Primary | PET-CT ORR at PRA According to the Lugano 2014 Criteria as Determined by an Independent Review Committee (IRC) (Cohort C) | 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days) | |
| Secondary | Maximum Serum Concentration (Cmax) of Mosunetuzumab IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Minimum Serum Concentration (Cmin) of Mosunetuzumab IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Area Under the Curve (AUC) of Mosunetuzumab IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Clearance (CL) of Mosunetuzumab IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Volume of Distribution at Steady State (Vss) of Mosunetuzumab IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Maximum Serum Concentration (Cmax) of Mosunetuzumab SC | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Time to Maximum Serum Concentration (Tmax) of Mosunetuzumab SC | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Minimum Serum Concentration (Cmin) of Mosunetuzumab SC | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Area Under the Curve (AUC) of Mosunetuzumab SC | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Clearance (CL) of Mosunetuzumab SC | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Volume of Distribution at Steady State (Vss) of Mosunetuzumab SC | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Maximum Serum Concentration (Cmax) of Polatuzumab Vedotin IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Minimum Serum Concentration (Cmin) of Polatuzumab Vedotin IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Area Under the Curve (AUC) of Polatuzumab Vedotin IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Clearance (CL) of Polatuzumab Vedotin IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) | |
| Secondary | Volume of Distribution at Steady State (Vss) of Polatuzumab Vedotin IV | At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03677154/registered